the Efficacy and Safety of CLAE in R/R T-ALL/LBL

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Clinical Trial

Official title: Clinical Observation on the Efficacy and Safety of CLAE Regimen (Cladribine + Cytarabine + Etoposide) in the Treatment of Relapsed/Refractory T- Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.

Clinical Trial Description

This study is a prospective, open, multiple -centered, sing-arm trial. The major aim of this studies to evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL. The study will include 50 subjects to receive CLAE regimen for reinduction chemotherapy. ;

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT04679506
• Study type: Observational [Patient Registry]
• Source: Peking University Third Hospital
• Contact: Hongmei Jing, MD, phD
• Phone: 15611908428
• Email: hongmeijing@bjmu.edu.cn
• Status: Not yet recruiting
• Start date: December 2020
• Completion date: December 2023